Oncology Drug Development Solutions

Providing Strong Support and Innovation in Oncology

CMIC Group’s specialized oncology staff assists with strategic development planning, including regulatory interaction, conducting clinical studies and post-marketing promotion for companies that wish to enter into the field of oncology. Our resources, with an established network of Key Opinion Leaders (KOLs) in hematologic malignancies and solid tumors, will benefit your oncology project from development to marketing.

Our Edge in Oncology Drug Development

Highly Specialized Oncology Eexpertise

Our team has average 10+ years of oncology experience and strong relationships with KOLs in Japan and Asia, allowing them to be on top of oncology trends. Our specialists have experiences of various study designs both of selected population and broad range of population.
Experience with gene therapy, immune therapy or biologic treatment studies and geographic experience, covering a wide range: from rare cancers to population-based cancers.

Joint Research on Blood Cancer with National Cancer Center Japan

In 2020, CMIC and the National Cancer Center Japan (NCC) signed joint research agreement regarding the use of data on cancer-related gene mutations in hematologic malignancies. Learn more about our oncology services.

Experience of Different Cancers

Hematologic Malignancies	Solid Tumor
Myelodysplastic syndrome	All solid cancers (all comers)
Primary Myelofibrosis	Non-small cell lung cancer
Chronic Myeloid Leukemia	Small cell lung cancer
Acute Myeloid Leukemia	Gastrointestinal stromal tumor
Ph-positive subtype of active lymphatic leukemia	Stomach cancer
Multiple myeloma	Hepatocellular carcinoma
Mature T-cell Lymphoma	Pancreatic cancer
Mature B-cell Lymphoma	Colon cancer
Hodgkin’s Lymphoma	Prostate cancer
	Breast cancer
	Biliary tract cancer
	Ovarian cancer
	Mesothelioma
	Melanoma
	Glioma
	Cancer of Unknown Primary